In situ gels based drug delivery systems

Current Drug Therapy

Volumn 6, Issue 3, 2011, Pages 213-222

  Venkatesh, Madhugiri P ^a   Liladhar, Purohit K ^a   Kumar, Teggin M P ^a   Shivakumar, Hosakote G ^a  

^a JSS COLLEGE OF PHARMACY   (India)

Author keywords

Drug delivery system; Gels; In situ; Mucosa

Indexed keywords

CHLORPHENIRAMINE MALEATE; CLARITHROMYCIN; HUMAN INSULIN; INDOMETACIN; LIDOCAINE; MITOMYCIN; OFLOXACIN; PARACETAMOL; TETRACYCLINE; TETRYZOLINE; TIMOLOL;

ARTICLE; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; EPITHELIUM; FLOW KINETICS; FOURIER TRANSFORM MASS SPECTROMETRY; GEL; GELATION; HUMAN; IN SITU GEL BASED DRUG DELIVERY SYSTEM; INFRARED SPECTROSCOPY; LAMINA PROPRIA; MUCOSA; MUSCULARIS MUCOSA; PRIORITY JOURNAL; SMOOTH MUSCLE; TEMPERATURE; VISCOSITY;

EID: 79959982302     PISSN: 15748855     EISSN: 10657630     Source Type: Journal    
DOI: 10.2174/157488511796392004     Document Type: Article

References (113)

1. Dunn RL, English JP, Cowsar DR, Vanderbilt DP. Biodegradable in situ forming implants and methods of producing the same. US Patent 4,938,763, July 3, 1990.
2. Shively ML, Coonts BA, Renner WD, Southard JL, Bennett AT. Physico-chemical characterization of a polymeric injectable implant delivery system. J Control Release 1995; 33: 237-243.
3. Eleaz RE, Kost J. Characterization of a polymeric PLGA-injectable implant delivery system for the controlled release of proteins. J Biomed Mater Res 2000; 50: 388-396.
4. Haglund BO, Joshi R, Himmelstein KJ. An in situ gelling system for parenteral delivery. J Control Release 1996; 41: 229-235.
5. Eliaz RE, Szoka FC. Robust and prolonged gene expression from injectable polymeric implants. Gene Ther 2002; 9: 1230-1237.
6. An Y, Hubbell JA. Intraarterial protein delivery via intimally adherent bilayer hydrogels. J Control Release 2000; 64: 205-215.
7. Ono K, Saito Y, Yura H, et al. Photocrosslinkable Chitosan as a biological adhesive. J Biomed Mater Res 2000; 49: 289-295.
8. Ishishara M, Nakanishi K, Ono K, et al. Photocrosslinkable Chitosan as a dressing for wound occlusion and accelerator in healing process. Biomaterials 2002; 23: 833-840.
9. Ishihara M, Obara K, Ishizuka T, et al. Controlled release of fibroblast growth factors and heparin from photocrosslinked Chitosan hydrogels and subsequent effect on in vivo vascularisation. J Biomed Mater Res 2002; 64A: 551-559.
10. Obara K, Ishihara M, Ishizuka T, et al. Photocrosslinkable Chitosan hydrogel containing firbroblast growth factor-2 astimulates wound healing in healing-impaired db/db mice. Biomaterials 2003; 24: 3437-3444.
11. Burkoth AK, Anseth KS. A Review of photocrosslinked Polyanhydrides: In situ forming degradable networks. Biomaterials 2000; 21: 2395-2404.
12. Rozier A, Mazuel C, Grove J, Plazonnet B. A novel, Ionactivated, in situ gelling polymer for ophthalmic vehicles. Effect on bioavailability of timolol. Int J Pharm 1989; 57: 163-168.
13. Cohen S, Lobel E, Trevgoda A, Paled Y. A novel in situ forming ophthalmic drug delivery system from alginates undergoing gelation in the eye. J Control Release 1997; 44: 201-28.
14. Kumar S, Haglund BO, Himmelstein KJ. In situ forming ophthalmic drug delivery. J Ocul Pharmacol 1994; 10: 47-56.
15. Srividya B, Cardoza RM, Amin PD. Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system. J Control Release 2001; 73: 205-211.
16. Taylor LD, Cerankowski LD. Preparation of films exhibiting a balanced temperature dependence to permeation by aqueous solutions-a study of lower consolute behaviour. J Polym Sci Polym Chem Ed 1975; 13: 2551-2570.
17. Heskins M, Guillet JE. Solution properties of poly (Nisopropylacrylamide). J Macromol Sci Chem 1968; 2: 1441-1455.
18. Schild HG. Poly (N-isopropylacrylamide): Experiment, theory and application. Prog Polym Sci 1992; 17: 163-169.
19. Hoffman AS. In: Controlled drug delivery-Challenges and Strategies; American Chemical Society, Washington 1997; pp. 485-498.
20. Mortensen K, Pederson JS. Structural study on the micelle formation of poly (ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) triblock copolymer in aqueous solution. Macromolecules 1993; 26: 805-812.
21. Wikipedia: The Free Encylcopedia. http://en.wikipedia.org/wiki/Mucus_membrane (Assessed Jan 04, 2010)
22. Saetfone MF. Progress and problems in ophthalmic drug delivery. Pharmatech Business Briefing 2002; May: 167-180.
23. Kaur IP, Smith R. Penetration enhancer and ocular ophthalmic drug delivery. Drug Dev Ind Pharm 2002; 28: 356-357.
24. Kaur IP, Kanwar M. Ocular preparation: the formulation approach. Drug Dev Ind Pharm 2002; 28: 373-378.
25. Joshi A, Ding S, Himmelstein KJ. Reversible gelation composition and method of use. US Patent No 5,252,318, October 12, 1993.
26. Kumar S, Haglund BO, Himmelstein KJ. In Situ Forming Gels for Ophthalmic Drug Delivery. J Ocul Pharmacol 1994; 10: 47-51.
27. Le Boularis C, Aear L, Zia H, Sado PA, Needham T, Leverge R. Ophthalmic drug delivery systems: Recent advances. Prog Retinal Eye Res 1998; 17: 33-58.
28. Carlfors J, Edman K, Peterson R, Jornving K. Rheological evaluation of Gelrite (R) in situ gels for ophthalmic use. Eur J Pharm Sci 1998; 6: 113-119.
29. Edsman K, Carlfors J, Peterson R. Rheological evaluation of poloxamer as an in situ gel for ophthalmic use. Eur J Pharm Sci 1998; 6: 105-112.
30. Paulsson M. Controlled release gel formulation for mucosal drug delivery. Acta Universitatis Upsaliensis Uppsala 2001; 9-52.
31. El-Kamel AH. In vitro and in vivo evaluation of Pluronic F-127based ocular delivery system for timolol maleate. Int J Pharm Sci 2005; 241: 48-53.
32. Wei G, Xu H, Ding PT, Li SM, Zheng JMJ. Thermosetting gels with modulated gelation temperature for ophthalmic use: The rheological and gamma scintigraphic studies. J Control Release 2002; 83: 65-69.
33. Alexandridis P, Hatton JA. Poly(ethylene oxide)-Poly(proplylene oxide)-Poly(ethylene oxide) block co-polymer surfactants in aqueous solutions and at interface thermodynamic structure, dynamic, and modelling. Colloid Surface 1995; 96: 1-46.
34. Furrer P, Plazonnet B, Mayer JM, Gurny R. Application of in vivo confocal microscopy to the objective evaluation of ocular irritation induced by surfactant. Int J Pharm Sci 2002; 207: 89-98.
35. Chem Chow PC, Frank SG. In vitro release of Lidocaine from Pluronic® F-127. Int J Pharm Sci 1981; 8: 89-99.
36. Miller SC, Donowan MD. Effect of poloxamer 407 gel on the miotic activities of pilocarpine nitrate in rabbit. Int J Pharm Sci 1982; 12: 147-152.
37. Wei G, Xu H, Ding PT, Li SM, Zheng JM. Thermosetting gels with modulated gelation temperature for ophthalmic use: The rheological and gamma scintigraphic studies. J Control Release 2002; 83: 65-74.
38. Harrington WF, Von Hippel PH. The structure of collagen and gelatin. Adv Protein Chem 1961; 16: 1-38.
39. Anderson NS, Campbell JW, Harding MM, Rees DA, Samuel JWB. X-ray diffraction studies of polysaccharide sulphates: double helix models for K- and I-_carrageenans. J Mol Biol 1969; 45: 85-99.
40. Heymann E. Studies on sol-gel transformations, I. The inverse sol-gel transformation of methylcellulose in water. Trans Faraday Soc 1935; 31: 846-864.
41. Sarkar N. Thermal gelation properties of methyl and hydroxypropyl methylcellulose. J Appl Polym Sci 1979; 24: 1073-1087.
42. Hoffman AS, Afrassiabi A, Dong LC. Thermally reversible hydrogels: II. Delivery and selective removal of substances from aqueous solutions. J Control Release 1986; 4: 213-222.
43. Hirotsu S, Hirokawa Y, Tanaka T. Volume-phase transitions of ionized N-isopropylacrylamide gels. Chem Phys 1987; 87: 1392-1395.
44. Feil H, Bae YH, Feijen J, Kim SW. Effect of comonomer hydrophilicity and ionization on the lower critical solution temperature of N-isopropylacrylamide copolymers. Macromolecules 1993; 26: 2496-500.
45. Lin HR, Sung KC. Carbopol/pluronic phase change solution for ophthalmic drug delivery. J Control Release 2000; 69: 379-385.
46. Sintzel MB, Bernatchez SF, Tabatabay C, Gurny R. Biomaterial in ophthalmic drug delivery. Eur J Pharm Biopharm 1996; 42: 358-374.
47. Zignari M, Tabatabay C, Gurny R. Topical semi-solid drug delivery: kinetic and tolerance of ophthalmic hydrogel. Adv Drug Deliver Rev 1995; 16: 51-69.
48. Ding S. Recent advances in ophthalmic drug delivery. Pharm Sci Technol Today 1998; 1: 328-35.
49. Gurny R. Preliminary study of prolonged acting drug delivery system for the treatment of glaucoma. Pharmaceutica Acta Helvetica 1981; 56(4-5): 130-2.
50. LeBourlais CA, Treupel-Acar L, Rhodes CT, Sado PA, Leverge R. New ophthalmic drug delivery system. Drug Dev Ind Pharm 1995; 21: 19-59.
51. Hui H-W, Robinson JR. Ocular drug delivery of progesterone using a bioadhesion polymer. Int J Pharm Sci 1985; 26: 203-213.
52. Davies NM, Fair SJ, Hadgraft J, Kellaway IW. Evaluation of mucoadhesive polymer in ocular drug delivery: Part 1, Viscous solution. Pharmaceut Res 1991; 8: 1039-1043.
53. Robinson JR, Mlynek GM. Bioadhesive and phase change polymer for ocular drug delivery. Adv Drug Deliver Rev 1995; 16: 147-152.
54. Kaur IP, Smith R. Penetration enhancer and ocular bioadhesives: Two new avenues for ophthalmic drug delivery. Drug Dev Ind Pharm 2002; 28: 353-369.
55. Peppas NA, Bures P, Leobandung W, Ichikawa H. Hydrogels in pharmaceutical formulations. Eur J Pharm Biopharm 2000; 50: 27-46.
56. Soppimath KS, Aminabhavi TM, Dave AM, Kumbar SG, Rudzinski WE. Stimulus-responsive "smart" hydrogels as novel drug delivery systems. Drug Dev Ind Pharm 2002; 28: 957-974.
57. Qiu Y, Park K. Environment-sensitive hydrogels for drug delivery. Adv Drug Deliver Rev 2001; 53: 321-339.
58. Aikawa K, Mitsutake A, Uda H, et al. In situ forming degradable networks and their application in tissue engineering and drug delivery. Int J Pharm 1998; 168: 181-188.
59. Dunn RL, English JP, Cowsar DR, Vanderbelt DP. Biodegradable in situ forming implants and methods of producing the same. US Patent. 4,938,763, July, 1990.
60. Dunn R, Hardee G, Eds. In situ forming biodegradable implants for controlled release veterinary applications. Controlled Release Society Inc. Proceedings of International Symposium on Bioactive Materials. May, 1995; New York.
61. Duysen EG, Whitman SL, Krinick NL, Fujita SM, Yewey GL. An injectable, biodegradable delivery system for antineoplastic agents. AAPS, American Association of Pharmaceutical Scientists, Presentation 7575. Pharm Res, June, 1994; Washington.
62. Sherman JM, Fujita SM. Localized delivery of bupivacaine from atrigel formulations for the management of postoperative pain. AAPS, American Association of Pharmaceutical Scientists, Presentation 7574. Pharm Res, June, 1994; Washington.
63. Dunn RL, Yewey GL, Eds. Bone regeneration with the Atrigel polymer system. In: Proceedings of Portland Bone Symposium, June, 1995; Portland, Oregon.
64. Frank KR, Duysen EG, Eds. Controlled release of bioactive growth factors from a biodegradable delivery system. American Association of Pharmaceutical Scientists, Presentation. Pharm Res 2070 June, 1994; Washington.
65. Lowe BK, Norton RL, Eds. The effects of gamma irradiation on poly D,L-lactide as a solid and in N-methyl 2-pyrrolidone solutions. In: Proceedings of 19th Annual Meeting of the Society of Biomaterials, April to May, 1993; Birmingham, Alabama, USA.
66. Dunn RL, Tipton AJ, Southard GL, Rogers JA. Biodegradable polymer composition. US Patent 3,599,552, Feb, 1997.
67. Bhardwaj TR, Kanwar M, Lal R, Gupta A. Natural gums and modified natural gums as sustained-release carriers. Drug Dev Ind Pharm 2000; 26: 1025-1038.
68. Guo JH, Skinner GW, Harcum WW, Barnum PE. Pharmaceutical applications of naturally occurring water-soluble polymers. Pharm Sci Technol Today 1998; 1: 254-261.
69. Rozier A, Mazuel C, Grove J, Plaronnet B. Gelrite®: A novel ionactivated in situ gelling effect bioavailability of timolol. Int J Pharm 1989; 57: 163-168.
70. Schenkar HI, Silver LH. Long term intraocular pressure lowering efficiency and safety of timolol maleate gel forming solution 0.5% compared with Timptic XE 0.5% in a 12 month study. Am J Ophthalmol 2000; 13: 145-150.
71. Anseth KS, Metters AT, Bryant SJ, Martens PJ, Elisseeff JH, Bowman CN. In situ forming degradable networks and their application in tissue engineering and drug delivery. J Control Release 2002; 78: 199-209.
72. Matsuda T. Device-directed therapeutic drug delivery systems. J Control Release 2002; 78: 125-131.
73. Obara K, Ishihara M, Ishizuka T, et al. Photocrosslinkable chitosan hydrogel containing fibroblast growth factor-2 stimulates wound healing in healing-impaired db/db mice. Biomaterials 2003; 24: 3437-3444.
74. Ricci EJ, Bentley MVLB, Farah M, Bretas RES, Marchetti JM. Rheological characterization of Poloxamer 407 lidocaine hydrochloride gels. Eur J Pharm Sci 2002; 17: 161-167.
75. Paavola A, Yliruusi J, Rosenberg P. Controlled release and dura mater permeability of lidocaine and ibuprofen from injectable poloxamer-based gels. J Control Release 1998; 52: 169-178.
76. Barichello JM, Morishita M, Takayama K, Nagai T. Absorption of insulin from Pluronic F-127 gels following subcutaneous administration in rats. Int J Pharm 1999; 184: 189-198.
77. Katakam M, Ravis WR, Banga AK. Controlled release of human growth hormone in rats following parenteral administration of poloxamer gels. J Control Release 1997; 49: 21-26.
78. DesNoyer JR, McHugh AJ. The effect of Pluronic on the protein release kinetics of an injectable drug delivery system. J Control Release 2003; 86: 15-24.
79. Kim YJ, Choi S, Koh JJ, Lee M, Ko KS, Kim SW. Controlled release of insulin from injectable biodegradable triblock copolymer. Pharm Res 2001; 18: 548-550.
80. Jeong B, Bae YH, Lee DS, Kim SW. Biodegradable block copolymers as injectable drug-delivery systems. Nature 1997; 388: 860-862.
81. Chenite A, Chaput C, Wang D, et al. Novel injectable neutral solutions of chitosan form biodegradable gels in situ. Biomaterials 2000; 21: 2155-2161.
82. Suisha F, Kawasaki A, Miyayaki S, et al. Xyloglucan gels as sustained release vehicles for the intraperitoneal administration of mitomycin C. Int J Pharm 1998; 172: 27-32.
83. Matschke C, Isele U, Hoogevest P Van, Fahr A. Sustained release in jectables formed in situ and their potential use for veterinary products. J Control Release 2002; 85: 1-15.
84. Wei G, Xu H, Ding PT, Li SM, Zheng JM. Thermosetting gels with modulated gelation temperature for ophthalmic use: the rheological and gamma scintigraphic studies. J Control Release 2002; 83: 65-74.
85. Ling HR, Sung KC. Carbopol/pluronic phase change solutions for ophthalmic drug delivery. J Control Release 2000; 69: 379-388.
86. El-Kamel AH. In vitro and in vivo evaluation of Pluronic F127- based ocular delivery system for timolol maleate. Int J Pharm 2002; 241: 47-55.
87. Miyazaki S, Suzuki S, Kawasaki A, Endo K, Takahashi A, Attwood D. In situ gelling xyloglucan formulations for sustainedrelease ocular delivery of pilocarpine hydrochloride. Int J Pharm 2001; 229: 29-36.
88. Burgalassi S, Chetoni P, Panichi L, Boldrini E, Saettone MF. Xyloglucan as a novel vehicle for timolol: pharmacokinetics and pressure lowering activity in rabbits. J Ocul Pharmacol Ther 2000; 16: 497-509.
89. Paulsson M, Hagerstrom H, Edsman K. Rheological studies of the gelation of deacetylated gellan gum (Gelrite®) in physiological conditions. Eur J Pharm Sci 1999; 9: 99-105.
90. Hartmann V, Keipert S. Physico-chemical, in vitro and in vivo characterization of polymers for ocular use. Pharmazie 2000; 55: 440-443.
91. Cohen S, Lobel E, Trevgoda A, Peled Y. A novel in situ forming ophthalmic drug delivery system from alginates undergoing gelation in the eye. J Control Release 1997; 44: 201-8.
92. Sechoy O, Tissie G, Sebastian C, Maurin F, Driot JY, Trinquand C. A new long acting ophthalmic formulation of Carteolol containing alginic acid. Int J Pharm 2000; 207: 109-116.
93. Srividya B, Cardoza RM, Amin PD. Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system. J Control Release 2001; 73: 205-211.
94. Kumar S, Haglund BO, Himmelstein KJ. In situ forming gels for ophthalmic drug delivery. J Ocul Pharmacol 1994; 10: 47-56.
95. Carelli V, Coltelli S, Di Colo G, Nannipieri E, Serafini MF. Silicone microspheres for pH-controlled gastrointestinal drug delivery. Int J Pharm 1999; 179: 73-83.
96. Kubo W, Miyazaki S, Attwood D. Oral sustained delivery of paracetamol from in situ-gelling gellan and sodium alginate formulations. Int J Pharm 2003; 258: 55-64.
97. Rajinikanth PS, Mishra B. Floating in situ gelling system for stomach site-specific delivery of clarithromycin to eradicate H. Pylori. J Control Release 2008; 125: 33-41.
98. Choi HG, Oh Y-K, Kim C-K. In situ gelling and mucoadhesive liquid suppository containing acetaminophen: enhanced bioavailability. Int J Pharm 1998; 165: 23-32.
99. Charrueau C, Tuleu C, Astre V, Grossiord J-L, Chaumeil JC. Poloxamer 407 as a thermogelling and adhesive polymer for rectal administration of short-chain fatty acids. Drug Dev Ind Pharm 2001; 27: 351-357.
100. Miyazaki S, Suisha F, Kawasaki A, Shirakawa M, Yamatoya K, Attwood D. Thermally reversible xyloglucan gels as vehicles for rectal drug delivery. J Control Release 1998; 56: 75-83.
101. Vermani K, Garg S. The scope and potential of vaginal drug delivery. Pharm Sci Technol Today 2000; 3: 359-364.
102. Chang JY, Oh Y-K, Kong HS, et al. Prolonged antifungal effects of clotrimazole-containing mucoadhesive thermosensitive gels on vaginitis. J Control Release 2002; 82: 39-50.
103. Miyazaki S, Tobiyama T, Takada M, Attwood D. Percutaneous absorption of indomethacin from pluronic F127 gels in rats. J Pharm Pharmacol 1995; 47: 455-457.
104. Pillai O, Panchagnula R. Transdermal delivery of insulin from poloxamer gel: ex vivo and in vivo skin permeation studies in rat using iontophoresis and chemical enhancers. J Control Release 2003; 89: 127-140.
105. Esposito E, Carotta V, Scabbia A, et al. Comparative analysis of tetracycline-containing dental gels: Poloxamer and monoglyceride based formulations. Int J Pharm 1996; 142: 9-23.
106. Kashyap N, Viswanad B, Sharma G, Bhardwaj V, Ramarao P, Kumar MNV. Design and evaluation of biodegradable, biosensitivein situ gelling system for pulsatile delivery of insulin. Biomaterials 2007; 28: 2051-2060.
107. Miyazaki S, Suisha F, Kawasaki N, Shirakawa M, Yamatoya K, Attwood D. Thermally reversible xyloglucan gels as vehicles for rectal drug delivery. J Control Release 1998; 56: 75-83.
108. Miyazaki S, Kawasaki N. Comparison of in situ gelling formulations for the oral delivery of cimetidine. Int J Pharm 2001; 220: 161-168.
109. Suisha F, Kawasaki N, Miyazaki S, et al. Xyloglucan gels as sustained release vehicles for the intraperitoneal administration of mitomycin C. Int J Pharm 1998; 172: 27-32.
110. Chandrashekhar G, Udupa N. Biodegradable injectable implant system for long term drug delivery using poly (lactic-co-glycolic) acid copolymers. J Pharm Pharmacol 1998; 48: 669-674.
111. Ramesh CR, Zentner GM, Jeong B. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties. US Patent 6,201,072, March 13, 2001.
112. Rathi R, Zentner C, Gaylen M, Jeong B. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties. US Patent 6,117,949, September 12, 2000.
113. Rathi R, Zentner C, Gaylen M. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties. US Patent 6,004,573, Dec 21, 1999.